OBJECTIVES: To find clinical factors related to administration of substandard treatment in older patients with head and neck cancer. STUDY DESIGN: Historic cohort. METHODS: Patients of 70 years of age of older with diagnosis of resectable head and neck cancer were included. Treatment offered to patients was classified as standard or substandard by experienced surgeons. Relation of age, clinical stage, comorbidities, performance status, and treatment with substandard treatment was explored. The effect of substandard treatment on survival was assessed. RESULTS: Three hundred twelve patients were included. Substandard treatment was offered to 19.9% of patients. Associated factors related to selection of substandard treatment were higher age, oro/hypopharynx tumor site, severe comorbidity, advanced clinical stage, and low Karnofsky Index. Patients submitted to substandard treatment had lower overall and cancer-specific survival (45.9% vs. 19.9% and 63.0% vs. 33.1%, respectively). CONCLUSION: Selection of substandard treatment decreases overall and cancer-specific survival. Selecting substandard treatment for reasons such as chronologic age, tumor site, or moderate or mild comorbidities worsen patient prognosis.
OBJECTIVES: To find clinical factors related to administration of substandard treatment in older patients with head and neck cancer. STUDY DESIGN: Historic cohort. METHODS:Patients of 70 years of age of older with diagnosis of resectable head and neck cancer were included. Treatment offered to patients was classified as standard or substandard by experienced surgeons. Relation of age, clinical stage, comorbidities, performance status, and treatment with substandard treatment was explored. The effect of substandard treatment on survival was assessed. RESULTS: Three hundred twelve patients were included. Substandard treatment was offered to 19.9% of patients. Associated factors related to selection of substandard treatment were higher age, oro/hypopharynx tumor site, severe comorbidity, advanced clinical stage, and low Karnofsky Index. Patients submitted to substandard treatment had lower overall and cancer-specific survival (45.9% vs. 19.9% and 63.0% vs. 33.1%, respectively). CONCLUSION: Selection of substandard treatment decreases overall and cancer-specific survival. Selecting substandard treatment for reasons such as chronologic age, tumor site, or moderate or mild comorbidities worsen patient prognosis.
Authors: Thomas T A Peters; Sophie F Post; Boukje A C van Dijk; Jan L N Roodenburg; Bernard F A M van der Laan; Paul M N Werker; Gyorgy B Halmos Journal: Eur Arch Otorhinolaryngol Date: 2014-09-13 Impact factor: 2.503
Authors: Thomas F Barrett; Angela L Mazul; Katelyn O Stepan; C Burton Wood; Randall C Paniello; Jose P Zevallos; Sean Massa; Ryan S Jackson; Nicole C Schmitt; Joseph Zenga; Stephen Y Kang; Patrik Pipkorn; Jason T Rich; Sidharth V Puram Journal: Oral Oncol Date: 2021-05-12 Impact factor: 5.972
Authors: Emilie A C Dronkers; Steven W Mes; Marjan H Wieringa; Marc P van der Schroeff; Robert J Baatenburg de Jong Journal: BMC Cancer Date: 2015-07-11 Impact factor: 4.430
Authors: Lies Pottel; Michelle Lycke; Tom Boterberg; Hans Pottel; Laurence Goethals; Fréderic Duprez; Sylvie Rottey; Yolande Lievens; Nele Van Den Noortgate; Kurt Geldhof; Véronique Buyse; Khalil Kargar-Samani; Véronique Ghekiere; Philip R Debruyne Journal: BMC Cancer Date: 2015-11-09 Impact factor: 4.430